IP Library › Granted Patent US 9,867,870
Granted Patent B2
US 9,867,870 · App. 15/480,986 · Granted Jan 16, 2018

Compositions and methods for treating hemophilia

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,867,870
App. No.
15/480,986
Granted
Jan 16, 2018
Kind
B2
Abstract

The present invention relates to compositions and methods for modulating coagulation through modulating the level or activity of NPP4.

Claims (7)

1. A method of treating hemophilia in a human subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an isolated soluble NPP4 polypeptide comprising amino acid residues 1-407 of SEQ ID NO:1.

2. The method of claim 1 , wherein the NPP4 polypeptide is a soluble recombinant NPP4 polypeptide.

3. The method of claim 1 , wherein said NPP4 polypeptide lacks the NPP4 transmembrane domain.

4. The method of claim 1 , wherein the NPP4 polypeptide consists of amino acid residues 1-407 of SEQ ID NO:1.

5. The method of claim 1 , wherein the NPP4 polypeptide is administered in combination with at least one other agent useful in treating bleeding.

6. The method of claim 1 , wherein the NPP4 polypeptide is administered acutely or chronically.

7. The method of claim 1 , wherein the NPP4 polypeptide is administered locally, regionally or systemically.

Assignments (1)
SECURITY INTEREST Recorded Apr 27, 2026
From: BIOMARIN PHARMACEUTICAL INC.; AMICUS THERAPEUTICS, INC.
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 075493/0968 →